- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study
-
- Gita Faghihi
- Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
-
- Azam Elahipoor
- Department of Dermatology, Qom University of Medical Sciences, Qom, Iran
-
- Fariba Iraji
- Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
-
- Shadi Behfar
- Department of Dermatology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
-
- Bahareh Abtahi-Naeini
- Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran
Search this article
Description
<jats:p><jats:italic>Introduction</jats:italic>. Actinic keratoses (AKs), a premalignant skin lesion, are a common lesion in fair skin. Although destructive treatment remains the gold standard for AKs, medical therapies may be preferable due to the comfort and reliability .This study aims to compare the effects of topical 1% colchicine gel and 3% diclofenac sodium gel in AKs.<jats:italic>Materials and Methods</jats:italic>. In this randomized double-blind study, 70 lesions were selected. Patients were randomized before receiving either 1% colchicine gel or 3% diclofenac sodium cream twice a day for 6 weeks. Patients were evaluated in terms of their lesion size, treatment complications, and recurrence at 7, 30, 60, and 120 days after treatment.<jats:italic>Results</jats:italic>. The mean of changes in the size was significant in both groups both before and after treatment (<0.001). The mean lesion size before treatment and at 30, 60, and 120 days was not different between the two groups (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:math>> 0.05). No case of erythema was seen in the colchicine group, while erythema was seen in 22.9% (eight cases) of patients in the diclofenac sodium group (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:math>= 0.005).<jats:italic>Conclusions</jats:italic>. 1% colchicine gel was a safe and effective medication with fewer side effects and lack of recurrence of the lesion.</jats:p>
Journal
-
- Advances in Medicine
-
Advances in Medicine 2016 1-6, 2016
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1362825893725859712
-
- ISSN
- 2314758X
- 23566752
-
- Data Source
-
- Crossref